Insilico Medicine’s PandaClaw: An Agentic AI for Therapeutic Discovery (opens in new tab)

For decades, the bottleneck in drug discovery wasn’t the biology; it was the translation. Getting from a disease hypothesis to a viable therapeutic target required researchers to speak two languages fluently—the molecular grammar of living systems and the computational dialect of machine learning. Insilico Medicine is a clinical-stage AI-driven drug discovery company based in Hong […] The post appeared first on <a href="